Glenmark Pharmaceuticals

Glenmark Pharma share price jumps 7% today on upbeat April-June quarter results

Glenmark Pharma's consolidated revenue stood at Rs 2,344.78 crore for the April-June quarter. The company had reported Rs 2,322.87 crore consolidated revenue in the year-ago period.

Stocks in focus: Rossari Biotech, Glenmark Pharma, L&T, HDFC AMC, Vodafone Idea, Axis Bank

ABB India, Biocon, HDFC Asset Management Company, AU Small Finance Bank, Dish TV, Mphasis, PNB Housing Finance, Radico Khaitan, Sterlite Technologies and Zensar Technologies, are among 49 companies that are scheduled to annou

कोविड19 की अन्य दवाओं से सस्ती है FabiFlu, संक्रमित मरीजों पर असर को लेकर नहीं किया है झूठा दवा: ग्लेनमार्क

कंपनी ने भारत के दवा महा नियंत्रक (डीसीजीआई) के एक नोटिस के जवाब में यह कहा.

ग्लेनमार्क ने COVID-19 दवा FabiFlu की कीमत 27% घटाई, अब एक टैबलेट का दाम हुआ 75 रु

ग्लेनमार्क ने फैबीफ्लू को पिछले माह 103 रुपये प्रति टैबलेट पर लॉन्च किया था.

Glenmark Pharmaceuticals share price rallies 15% as firm launches COVID-19 drug Favipiravir

Glenmark Pharma stock has gained 180 per cent in less than three months from its 52-week low of Rs 168 apiece, taking the market capitalisation of the company to Rs 13,274.60 crore

Stocks in focus: Glenmark Pharma, Cipla, Reliance Capital, HDFC Bank shares to remain in news today

Market sentiments would be swayed by global cues, development around geopolitical tensions, coronavirus cases, monthly F&O expiry and foreign fund movement

Glenmark ने COVID-19 दवा के ट्रायल का तीसरा दौर किया शुरू, जुलाई-अगस्त तक सामने आएगा रिजल्ट

Glenmark launches digital dose inhaler for asthma patients

Glenmark Pharmaceuticals today launched 'Digihaler', the country's first digital dose inhaler (DDI), for asthma and chronic obstructive pulmonary disease (COPD) patients.

Glenmark records a 29.89 per cent growth in Q4 FY 15-16

India Business grew at 22.52 per cent to Rs 5,397.72 million for the quarter and to Rs 21,092.72 million for the year

Glenmark Pharma’s drugs gets tentative ANDA approval

The approvals are for norethindrone acetate and for adapalene and benzoyl peroxide gel

Glenmark gets USFDA tentative nod for oral contraceptives

Glenmark Pharmaceuticals has received tentative nod from the US health regulator for generic version of oral contraceptive tablets Lo Loestrin Fe.

Glenmark receives US FDA approval for bendamustine hydrochloride injection

It is Glenmark’s first injectable approval in the US

Glenmark Pharmaceuticals introduce EMI scheme for cancer treatment drugs

Glenmark Pharmaceuticals has rolled out an EMI scheme for cancer patients in order to help them continue the treatment and meet the high cost of medication

Glenmark settles patent suit with Forest Lab over Savella drug

Glenmark will have the option to market and distribute its milnacipran hydrochloride tablets or an authorised generic version of Savella tablets

Glenmark receives ANDA approval for clotrimazole and betamethasone dipropionate cream

According to IMS, the Lotrisone cream market achieved annual sales of approximately $82.4 million Glenmark Pharmaceuticals, USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U

Glenmark share price jumps 5% on tentative USFD nod for Lacosamide Tablets

Glenmark Pharmaceuticals share price gained as much as 4.5 per cent in the morning trade on Friday after the company informed stock exchanges that Glenmark Pharmaceuticals Inc., USA has been granted tentative approval by the

Glenmark Pharmaceuticals Q2 net profit up 20% at Rs 198 cr

Glenmark Pharmaceuticals today reported 19.81 per cent increase in consolidated net profit to Rs 197.78 crore for the second quarter ended September 30, driven by good growth in India, US and Europe.

Glenmark Pharmaceuticals inks pact with Celon for generic Seretide Accuhaler

Glenmark Pharmaceuticals has entered into an agreement with Poland based Celon Pharma to develop and market a generic version of GlaxoSmithKline's Seretide Accuhaler in Europe used for treatment of lung diseases.

Rosier year-end seen for Lupin, Aurobindo, Glenmark thanks to faster US approvals

India's pharmaceutical industry is expected to see sales and profit growth accelerate in the second half of the year, thanks to a pickup in the pace of U.S. approvals for new drugs, offsetting any downturn in volatile emergin

Delhi HC restrains Glenmark from business of anti-diabetes drugs

Earlier, in an interim order, a division bench of the Delhi high Court had restrained Glenmark from making or selling its drug, used for treatment of Type-2 diabetes.

Glenmark Pharmaceuticals gets USFDA nod for fungal infections treatment drug

Glenmark Pharmaceuticals today said it has received final approval from the US health regulator for Voriconazole Tablets, used to treat fungal infections.

Stocks that are in focus today: Cipla, ONGC, Wipro and more

Cipla stocks will be in focus today as the the Indian generic drugmaker on Friday informed BSE that its UK arm, Cipla EU, has entered into definitive agreements to acquire two US-based companies InvaGen Pharmaceuticals Inc an

Glenmark’s novel monoclonal antibody GBR 830 to enter phase II clinical studies

GBR 830 targets activated T cells, which drives the pathology in most autoimmune diseases including rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease Glenmark Pharmaceuticals’ GBR 830, a novel mono

Glenmark Pharma receives ANDA approval for Drospirenone and Ethinyl Estradiol tabs

Plans to commence shipping of the tablets USP, 3 mg/0.02 mg immediately Glenmark Pharmaceuticals, has been granted final approval by the United States Food & Drug Administration (US FDA) for Drospirenone and Ethinyl Estra

Glenmark plea to use drug stock rejected

Supreme Court on Tuesday rejected generic drug maker Glenmark Pharmaceuticals’ plea seeking permission to utilise its existing stock of the active ingredient sitagliptin, used for the manufacture of its anti-diabetes drugs

Glenmark’s consolidated revenue increases by 11.32 per cent to Rs 16,552.48 million in Q1 FY 15-16

Consolidated net profit for Q1 FY 15-16 was Rs 1909.38 million Glenmark Pharmaceuticals announced its results for the first quarter ended June 30, 2015. For the first quarter ended June 30, 2015, Glenmark’s consolidated rev

Glenmark Pharma gets ANDA approval for Calcipotriene cream

Glenmark Pharmaceuticals, US (Glenmark) has been granted final approval by the United States Food and Drug Administration (US FDA) for Calcipotriene cream, 0.005 per cent, the therapeutic equivalent of Dovonex cream, 0.005 pe